Simon S R, Black H R, Moser M, Berland W E
Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn.
Arch Intern Med. 1992 Aug;152(8):1698-700.
To assess the prevalence of cough as a side effect of angiotensin-converting enzyme inhibitor antihypertensive therapy, we reviewed 300 consecutive patient charts from a private practice and 200 consecutive patient charts from a university-based referral center for hypertension. Incidence of definite angiotensin-converting enzyme inhibitor-induced cough in the private practice was 25% and in the university practice, 7%, with an additional 6% of university-practice patients reporting a possible angiotensin-converting enzyme-inhibitor induced cough. This incidence is considerably greater than listed in the Physicians' Desk Reference. Reasons for the variability in incidence as reported in the literature are explored. Clinicians must be aware of this potentially disturbing side effect of angiotensin-converting enzyme inhibitors to avoid expensive and unnecessary diagnostic evaluations.
为评估咳嗽作为血管紧张素转换酶抑制剂抗高血压治疗副作用的发生率，我们回顾了一家私人诊所连续300例患者的病历以及一家大学高血压转诊中心连续200例患者的病历。私人诊所中明确由血管紧张素转换酶抑制剂引起咳嗽的发生率为25%，大学诊所为7%，另外有6%的大学诊所患者报告可能是由血管紧张素转换酶抑制剂引起的咳嗽。这一发生率明显高于《医师案头参考》中列出的数字。本文探讨了文献中报道的发生率存在差异的原因。临床医生必须意识到血管紧张素转换酶抑制剂这种潜在的令人不安的副作用，以避免进行昂贵且不必要的诊断评估。
